SCHEMBL5046796

SCHEMBL5046796

CCCCCCSc1nccc(CN2CCOCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.47
THRB P10828 5/20 0.41
RAC1 P63000 1/20 0.40
ALOX15 P16050 1/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 2/20 0.40
TSHR P16473 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
HTR2A P28223 1/20 0.39
SCN1A P35498 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5042952 0.83 THRB (0.43) CXCR4THRBRAC1RAB9AMEN1
SCHEMBL5042209 0.82 HSD17B10 (0.46) CXCR4THRBMEN1KMT2ASMN1; SMN2
SCHEMBL5046102 0.81 THRB (0.41) CXCR4THRBRAB9AMEN1TSHR
SCHEMBL5049081 0.81 HSD17B10 (0.47) CXCR4THRBALOX15RAB9AMEN1
SCHEMBL5043353 0.78 ALDH1A1 (0.44) CXCR4THRBRAC1MEN1TSHR
SCHEMBL5046236 0.78 HSD17B10 (0.46) CXCR4THRBMEN1KMT2ASMN1; SMN2
SCHEMBL5050442 0.78 GPR84 (0.38) THRBALOX15MEN1TSHRKMT2A
SCHEMBL5042347 0.77 HSD17B10 (0.48) CXCR4THRBALOX15RAB9ASMN1; SMN2
SCHEMBL6022036 0.73 THRB (0.48) THRBRAB9AMEN1KMT2ANPC1
SCHEMBL6022136 0.71 ALOX15 (0.51) ALOX15RAB9AMEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US claimed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US claimed
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US disclosed
EP-1725239-B1 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY HOFFMANN LA ROCHE (CH) 2007-07-18 EP disclosed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors CHRNA2, CNR2, GABRB2 CXCR4 371/4885THRB 434/4885RAC1 2727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.